158. Tuberous sclerosis Disease details / Clinical trials / Drug dev / DR info


Clinical trials : 112 Drugs : 71 - (DrugBank : 19) / Drug target genes : 35 - Drug target pathways : 118

Drugs and their primary sponsors and trial info
AED   
   Peking Union Medical College Hospital
      2017   Phase 2   NCT03356769   China;
Afinitor   
   Cardiff University
      2012   Phase 2   EUCTR2011-004854-25-GB   United Kingdom;
   Novartis Pharma Services AG
      -   Phase 3   EUCTR2010-022583-13-FR   Belgium;Czech Republic;France;Germany;Greece;Hungary;Italy;Spain;
      -   Phase 3   EUCTR2008-002113-48-DE   Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States;
Afinitor 5mg Tablets   
   Novartis Pharma Services AG
      2009   Phase 3   EUCTR2008-002113-48-GB   Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States;
Antiepileptic drug (1 to 3 only)   
   Novartis Pharmaceuticals
      2013   Phase 3   NCT01713946   Argentina;Australia;Belgium;Canada;Colombia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
Aspirin   
   Peking Union Medical College Hospital
      2017   Phase 2   NCT03356769   China;
Basimglurant   
   Noema Pharma AG
      2021   Phase 2   NCT05059327   -
Bumetanide   
   UMC Utrecht
      2017   Phase 2   EUCTR2016-002408-13-NL   Netherlands;
CBD - Oral Solution, is known as Epidyolex 100 mg/ml oral solution,   
   GW Research Ltd.
      -   Phase 3   EUCTR2015-002154-12-PL   Australia;Netherlands;Poland;Spain;United Kingdom;United States;
CBD-Oral Solution, is known as Epidiolex, and is the approved name in the USA.   
   GW Research Ltd.
      2017   Phase 3   EUCTR2015-002154-12-NL   Australia;Netherlands;Poland;Spain;United Kingdom;United States;
Cannabidiol   
   GW Research Ltd
      2021   Phase 4   NCT05044819   United States;
Cannabidiol (CBD)   
   GW Research Ltd
      -   Phase 3   EUCTR2020-002132-67-Outside-EU/EEA   United States;
   GW Research Ltd.
      2017   Phase 3   EUCTR2015-002154-12-NL   Australia;Netherlands;Poland;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002154-12-ES   Australia;France;Netherlands;Poland;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2015-002154-12-PL   Australia;Netherlands;Poland;Spain;United Kingdom;United States;
Cannabidiol Oral Solution, is known as Epidyolex 100 mg/mL oral solution and is the approved name in the EU. Epidiolex (cannabidiol) oral solution is the approved name in the US.   
   GW Research Ltd
      -   Phase 3   EUCTR2020-002132-67-Outside-EU/EEA   United States;
Certican 1 mg tablets   
   Novartis Pharma Services AG
      2011   -   EUCTR2007-006997-27-BE   Belgium;Germany;Italy;Netherlands;United Kingdom;
Doxycycline   
   University of Nottingham
      2009   Phase 4   NCT00989742   United Kingdom;
Everolimus   
   Cardiff University
      2012   Phase 2   EUCTR2011-004854-25-GB   United Kingdom;
   Children's Hospital Medical Center, Cincinnati
      2010   Phase 1/Phase 2   NCT01070316   United States;
      2007   Phase 1/Phase 2   NCT00411619   United States;
   Dana-Farber Cancer Institute
      2014   Phase 2   NCT02201212   United States;
   Department of Pharmacy, Peking University First Hospita
      2020   Phase 4   ChiCTR2000039523   China;
   Department of Urology, Keio University School of Medicine
      2013   -   JPRN-UMIN000011559   Japan;
   Erasmus Medical Center
      2012   Phase 2/Phase 3   NCT01730209   Netherlands;
   General Hospital of PLA
      2016   -   ChiCTR-OPN-16008236   China;
   Hospices Civils de Lyon
      2020   Phase 2/Phase 3   NCT02860494   France;
   Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
      2013   Phase 2   NCT01929642   United States;
   NOVARTIS FARMA
      2011   -   EUCTR2010-022583-13-IT   Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain;
      2009   -   EUCTR2008-002113-48-IT   France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2007-006997-27-IT   Belgium;Germany;Italy;Netherlands;United Kingdom;
   NYU Langone Health
      2014   Phase 2   NCT02451696   United States;
   Novartis Pharma Services AG
      2011   -   EUCTR2007-006997-27-BE   Belgium;Germany;Italy;Netherlands;United Kingdom;
      2010   -   EUCTR2007-006997-27-NL   Australia;Belgium;Canada;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;
      2010   -   EUCTR2007-006997-27-DE   Belgium;Germany;Italy;Netherlands;United Kingdom;
      2009   Phase 3   EUCTR2008-002113-48-GB   Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States;
      2009   Phase 3   EUCTR2007-006997-27-GB   Belgium;Germany;Italy;Netherlands;United Kingdom;
   Novartis Pharmaceuticals
      2022   Phase 4   NCT05252585   -
      2018   Phase 4   NCT03525834   China;
      2017   Phase 3   NCT02962414   Australia;Belgium;Canada;Colombia;France;Hungary;Italy;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2009   Phase 3   NCT00789828   Australia;Belgium;Canada;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;United States;
Everolimus (RAD001)   
   Cardiff University
      2012   Phase 2   NCT01954693   United Kingdom;
   Children's Hospital Medical Center, Cincinnati
      2008   Phase 1/Phase 2   NCT00792766   United States;
   Novartis Pharmaceuticals
      2009   Phase 3   NCT00790400   Canada;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
Everolimus 2mg dispersible tablet   
   Novartis Pharma Services AG
      2013   Phase 3   EUCTR2011-000860-90-DE   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Everolimus Oral Product   
   University of Pennsylvania
      2014   Phase 1/Phase 2   NCT02061397   United States;
GWP42003-P   
   GW Research Ltd
      2021   Phase 3   NCT04485104   United States;
      2016   Phase 3   NCT02544763   Australia;Netherlands;Poland;Spain;United Kingdom;United States;
      2016   Phase 3   NCT02544750   United States;
      -   Phase 3   EUCTR2020-002132-67-Outside-EU/EEA   United States;
   GW Research Ltd.
      2017   Phase 3   EUCTR2015-002154-12-NL   Australia;Netherlands;Poland;Spain;United Kingdom;United States;
      2016   Phase 3   EUCTR2015-002154-12-ES   Australia;France;Netherlands;Poland;Spain;United Kingdom;United States;
      -   Phase 3   EUCTR2015-002154-12-PL   Australia;Netherlands;Poland;Spain;United Kingdom;United States;
Ganaxolone   
   Marinus Pharmaceuticals
      2020   Phase 2   NCT04285346   United States;
Gold   
   An Zhen Hospital affiliated to Capital Medical University, Beijing
   Beijing Key Laboratory of Fetal Heart Diseases and Maternal-Fetal Medicine
L04AA18   
   Erasmus MC - Department of Neurology
      2012   -   EUCTR2010-019519-39-NL   Netherlands;
Metformin (generic)   
   University Hospitals Bristol NHS Foundation Trust
      2012   Phase 4   EUCTR2011-001319-30-GB   United Kingdom;
Metformin hydrochloride   
   University Hospitals Bristol NHS Foundation Trust
      2012   Phase 4   EUCTR2011-001319-30-GB   United Kingdom;
NPC-12G gel   
   Nobelpharma
      2015   Phase 3   NCT02635789   Japan;
      2015   Phase 3   NCT02634931   Japan;
Open label RAD001 (only used for post-extension phase)   
   Novartis Pharmaceuticals
      2013   Phase 3   NCT01713946   Argentina;Australia;Belgium;Canada;Colombia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
Petrolatum   
   Department of DermatologyGraduate School of Medicine, Osaka University
      2009   Phase 2,3   JPRN-UMIN000002844   Japan;
Propranolol   
   University Hospital, Bordeaux
      2015   Phase 2   NCT02104011   France;
RAD001   
   Cardiff University
      2012   Phase 2   EUCTR2011-004854-25-GB   United Kingdom;
   Children's Hospital Medical Center, Cincinnati
      2005   Phase 1/Phase 2   NCT00457964   United States;
   Mustafa Sahin
      2011   Phase 2   NCT01289912   United States;
   NOVARTIS FARMA
      2013   Phase 3   EUCTR2011-000860-90-IT   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2011   -   EUCTR2010-022583-13-IT   Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain;
      2009   -   EUCTR2008-002113-48-IT   France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2007-006997-27-IT   Belgium;Germany;Italy;Netherlands;United Kingdom;
   Novartis Farmacéutica S.A
      2017   Phase 3   EUCTR2016-002977-37-ES   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
   Novartis Farmacéutica, S.A
      2013   -   EUCTR2012-005397-63-ES   Spain;
   Novartis Farmacéutica, S.A.
      2013   Phase 3   EUCTR2011-000860-90-ES   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
   Novartis Pharma AG
      2017   Phase 3   EUCTR2016-002977-37-HU   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002977-37-GB   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002977-37-FR   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002977-37-BE   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2016-002977-37-PL   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
   Novartis Pharma Services AG
      2014   Phase 3;Phase 4   EUCTR2013-003795-13-BE   Belgium;Canada;Poland;Russian Federation;United States;
      2014   Phase 3   EUCTR2011-000860-90-IE   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-000860-90-NL   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-000860-90-HU   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-000860-90-GR   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-000860-90-GB   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-000860-90-DK   Argentina;Belgium;Colombia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Spain;Taiwan;Turkey;United Kingdom;
      2013   Phase 3   EUCTR2011-000860-90-DE   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-000860-90-BE   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-022583-13-CZ   Belgium;Czech Republic;France;Germany;Greece;Hungary;Italy;Spain;
      2011   Phase 3   EUCTR2010-022583-13-BE   Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain;
      2011   -   EUCTR2010-022583-13-HU   Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain;
      2011   -   EUCTR2010-022583-13-GR   Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain;
      2011   -   EUCTR2007-006997-27-BE   Belgium;Germany;Italy;Netherlands;United Kingdom;
      2010   -   EUCTR2008-002113-48-NL   France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2010   -   EUCTR2007-006997-27-NL   Australia;Belgium;Canada;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;
      2010   -   EUCTR2007-006997-27-DE   Belgium;Germany;Italy;Netherlands;United Kingdom;
      2009   Phase 3   EUCTR2008-002113-48-GB   Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-002113-48-FR   France;Germany;Italy;Netherlands;Spain;United Kingdom;
      -   Phase 3   EUCTR2013-003795-13-PL   Belgium;Canada;Poland;Russian Federation;United States;
      -   Phase 3   EUCTR2010-022583-13-FR   Belgium;Czech Republic;France;Germany;Greece;Hungary;Italy;Spain;
      -   Phase 3   EUCTR2008-002113-48-DE   Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States;
RAD001 2,   
   Novartis Pharma Services AG
      -   -   EUCTR2010-022583-13-DE   Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain;
RAD001 round tablets   
   Novartis Pharma Services AG
      2009   Phase 3   EUCTR2007-006997-27-GB   Belgium;Germany;Italy;Netherlands;United Kingdom;
RAPAMUNE 1 mg/ml oral solution   
   The Children's Memorial Health Institute
      -   Phase 2;Phase 3   EUCTR2020-003231-19-PL   Poland;
Rapamune   
   Erasmus MC
      2011   -   EUCTR2010-022655-29-NL   Netherlands;
   FUNDACIÓ PUIGVERT
      2008   -   EUCTR2007-005978-30-ES   Spain;
   Le Bonheur Children's Hospital
      2013   Phase 1   NCT01853423   United States;
Rapamune 1 mg/ml solución oral   
   Fundación Investigación Hospital Ramón y Cajal
      2012   -   EUCTR2011-006308-12-ES   Spain;
Rapamycin   
   Chinese PLA General Hospital
      2015   -   ChiCTR-OOB-15006535   China;
   Department of Dermatology Graduate School of Medicine, Osaka University
      2014   Phase 2,3   JPRN-UMIN000015114   Japan;
      2011   Phase 2,3   JPRN-UMIN000006108   Japan;
   Department of DermatologyGraduate School of Medicine, Osaka University
      2009   Phase 2,3   JPRN-UMIN000002844   Japan;
   Dermatology Specialties Limited Partnership
      2019   Phase 2/Phase 3   NCT03826628   Australia;Czechia;Hungary;New Zealand;Serbia;Slovakia;Spain;Taiwan;United Kingdom;United States;
   The University of Texas Health Science Center, Houston
      2012   Phase 2   NCT01526356   Australia;United States;
Rapamycin cream, topical, , w/w   
   DSLP
      2019   Phase 2;Phase 3   EUCTR2019-000752-34-SK   Australia;Hungary;New Zealand;Slovakia;Spain;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2019-000752-34-HU   Australia;Hungary;New Zealand;Slovakia;Spain;United Kingdom;United States;
   Dermatology Specialities Limited Partnership (DSLP)
      -   Phase 2;Phase 3   EUCTR2019-000752-34-CZ   Australia;Czech Republic;Hungary;New Zealand;Serbia;Slovakia;Spain;United States;
Rapamycin, sirolimus   
   Children's Hospital Medical Center, Cincinnati
      2002   Phase 2   NCT00457808   United States;
Rapamycin-calcitriol combination   
   National Taiwan University Hospital
      2013   Phase 3   NCT03140449   -
SABRIL 500 mg, granules for oral solution   
   The Children's Memorial Health Institute
      -   Phase 2;Phase 3   EUCTR2020-003231-19-PL   Poland;
SOC   
   GW Research Ltd
      2021   Phase 3   NCT04485104   United States;
Simvastatin   
   University of Pennsylvania
      2014   Phase 1/Phase 2   NCT02061397   United States;
Sirolimus   
   Aucta Pharmaceuticals, Inc
      2017   Phase 2   NCT03363763   China;United States;
   Cardiff University
      2005   Phase 2   NCT00490789   United Kingdom;
   Darcy Krueger
      2021   Phase 2   NCT05104983   United States;
   Department of DermatologyGraduate School of Medicine, Osaka University
      2013   Phase 1,2   JPRN-UMIN000012420   Japan;
   FUNDACIÓ PUIGVERT
      2008   -   EUCTR2007-005978-30-ES   Spain;
   Fundacio Puigvert
      2008   Phase 4   NCT01217125   -
   Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
      2013   Phase 2   NCT01929642   United States;
   West China Hospital, Sichuan University
      2020   -   ChiCTR2000031984   China;
Sirolimus Oral Product   
   University of Pennsylvania
      2014   Phase 1/Phase 2   NCT02061397   United States;
Skincerity plus sirolimus/rapamycin   
   The University of Texas Health Science Center, Houston
      2009   Phase 1   NCT01031901   United States;
Skinercity plus sirolimus/rapamycin   
   The University of Texas Health Science Center, Houston
      2009   Phase 1   NCT01031901   United States;
TAVT-18 (sirolimus)   
   Children's Hospital Medical Center, Cincinnati
      2020   Phase 1/Phase 2   NCT04595513   United States;
Tacrolimus   
   Department of DermatologyGraduate School of Medicine, Osaka University
      2009   Phase 2,3   JPRN-UMIN000002844   Japan;
Turmeric   
   NYU Langone Health
      2018   -   NCT03254680   United States;
Vigabatrin   
   Martina Bebin
      2016   Phase 2   NCT02849457   United States;
   University of Pennsylvania
      2010   Phase 4   NCT01266291   United States;
Vigabatrin (Sabril)   
   The Children's Memorial Health Institute
      2014   -   EUCTR2013-005528-40-NL   Belgium;Netherlands;
Vigabatrin (sabril)   
   Vrije Universiteit Brussel
      2014   -   EUCTR2013-005528-40-BE   Belgium;Netherlands;
Votubia   
   Erasmus MC - Department of Neurology
      2012   -   EUCTR2010-019519-39-NL   Netherlands;
   NOVARTIS PHARMA AG
      2019   Phase 3   EUCTR2016-002977-37-IT   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
   Novartis Farmacéutica S.A
      2017   Phase 3   EUCTR2016-002977-37-ES   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
   Novartis Farmacéutica, S.A
      2013   -   EUCTR2012-005397-63-ES   Spain;
   Novartis Pharma AG
      2017   Phase 3   EUCTR2016-002977-37-HU   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002977-37-GB   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002977-37-FR   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-002977-37-BE   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2016-002977-37-PL   Australia;Belgium;Canada;Colombia;Denmark;France;Greece;Hungary;Japan;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
   Novartis Pharma Services AG
      2014   Phase 3;Phase 4   EUCTR2013-003795-13-BE   Belgium;Canada;Poland;Russian Federation;United States;
      2014   Phase 3   EUCTR2011-000860-90-IE   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-000860-90-NL   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-000860-90-HU   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-000860-90-GB   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2011-000860-90-DK   Argentina;Belgium;Colombia;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Spain;Taiwan;Turkey;United Kingdom;
      2013   Phase 3   EUCTR2011-000860-90-BE   Argentina;Australia;Belgium;Canada;Colombia;Denmark;Germany;Greece;Hungary;Ireland;Italy;Japan;Korea, Republic of;Netherlands;Russian Federation;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2011   Phase 3   EUCTR2010-022583-13-BE   Belgium;Czech Republic;Germany;Greece;Hungary;Italy;Spain;
      -   Phase 3   EUCTR2013-003795-13-PL   Belgium;Canada;Poland;Russian Federation;United States;